-
Kenya's economy faces climate change risks: World Bank
-
Trump admin halts US offshore wind projects citing 'national security'
-
Fuming Denmark summons US ambassador over Greenland envoy
-
Outcry follows CBS pulling program on prison key to Trump deportations
-
Sri Lanka cyclone caused $4.1 bn damage: World Bank
-
Billionaire Ellison offers personal guarantee for son's bid for Warner Bros
-
Tech stocks lead Wall Street higher, gold hits fresh record
-
Telefonica to shed around 5,500 jobs in Spain
-
EU slams China dairy duties as 'unjustified'
-
Stocks diverge as rate hopes rise, AI fears ease
-
Swiss court to hear landmark climate case against cement giant
-
Asian markets rally with Wall St as rate hopes rise, AI fears ease
-
As US battles China on AI, some companies choose Chinese
-
AI resurrections of dead celebrities amuse and rankle
-
Third 'Avatar' film soars to top in N. American box office debut
-
China's rare earths El Dorado gives strategic edge
-
Wheelchair user flies into space, a first
-
French culture boss accused of mass drinks spiking to humiliate women
-
US Afghans in limbo after Washington soldier attack
-
Nasdaq rallies again while yen falls despite BOJ rate hike
-
US university killer's mystery motive sought after suicide
-
IMF approves $206 mn aid to Sri Lanka after Cyclone Ditwah
-
Rome to charge visitors for access to Trevi Fountain
-
Stocks advance with focus on central banks, tech
-
Norway crown princess likely to undergo lung transplant
-
France's budget hits snag in setback for embattled PM
-
Volatile Oracle shares a proxy for Wall Street's AI jitters
-
Japan hikes interest rates to 30-year-high
-
Brazil's top court strikes down law blocking Indigenous land claims
-
'We are ghosts': Britain's migrant night workers
-
Asian markets rise as US inflation eases, Micron soothes tech fears
-
Trump signs $900 bn defense policy bill into law
-
EU-Mercosur deal delayed as farmers stage Brussels show of force
-
Harrison Ford to get lifetime acting award
-
Trump health chief seeks to bar trans youth from gender-affirming care
-
Argentine unions in the street over Milei labor reforms
-
Brazil open to EU-Mercosur deal delay as farmers protest in Brussels
-
Brussels farmer protest turns ugly as EU-Mercosur deal teeters
-
US accuses S. Africa of harassing US officials working with Afrikaners
-
ECB holds rates as Lagarde stresses heightened uncertainty
-
Trump Media announces merger with fusion power company
-
Stocks rise as US inflation cools, tech stocks bounce
-
Zelensky presses EU to tap Russian assets at crunch summit
-
Danish 'ghetto' residents upbeat after EU court ruling
-
ECB holds rates but debate swirls over future
-
Bank of England cuts interest rate after UK inflation slides
-
Have Iran's authorities given up on the mandatory hijab?
-
British energy giant BP extends shakeup with new CEO pick
-
EU kicks off crunch summit on Russian asset plan for Ukraine
-
Sri Lanka plans $1.6 bn in cyclone recovery spending in 2026
Brazilian ritual root gets second life as potential anti-depressant
Long used in Indigenous Brazilian rituals, the jurema preta plant, which contains a potent psychedelic, is gaining ground as a potential treatment for depression.
At street stalls where medicinal herbs are sold, customers can buy the plant's root which contains dimethyltryptamine (DMT), a hallucinogenic substance that researchers say could be used to alleviate symptoms.
Following instructions he found on the internet, Guaracy Carvajal extracted DMT at home in 2016 from roots he bought on the street.
The 31-year-old software programmer, who had tried various treatment for chronic depression he has suffered since adolescence, said the drug makes it "feel like you've solved something in your life."
Physicist Draulio Araujo, who has conducted extensive research on the drug, said "the response is rapid. One day after treatment, (patients) already showed a significant improvement in their depression symptoms."
Yet he also warned that it "is not a magic cure" and that psychedelics "are not for everyone."
As a researcher at the Brain Institute of the Federal University of Rio Grande do Norte, Araujo and his team treated 14 people with the drug for six months.
The patients inhaled vaporized DMT, under medical supervision.
"It's common for our patients to say that something changed, that a key opened something," he said.
His patients also received psychological therapy, and some continued with conventional pharmaceutical drugs.
Neuroscientist Fernanda Palhano-Fontes, also of the Brain Institute, said "we have patients who improve significantly, others who don't improve at all."
Araujo's findings were published in the scientific journal Nature in April. In 2024, he published another study with promising results in the journal Psychedelic Medicine.
As for Carvajal, who stopped using jurema preta some time ago, he said the drug really allows a person to "start to have a lighter life."
It helped him get through a time when he was in "a state of questioning myself" about "work, day-to-day life," he said.
- Spiritual channels -
Brazil occupies a fairly prominent place in DMT research due to the substance's prominence in society, Araujo said.
While there is no ban on the cultivation or possession of jurema, which is also known as Mimosa tenuiflora, consumption of DMT is prohibited, except for religious and scientific use.
Jurema's roots are combined with other plants in a wine-like beverage that is consumed at rituals that include dancing and drums, part of Indigenous tradition in northeast Brazil where the plant grows.
"It's not hallucination," said Joyce Souza, a young woman attending a jurema ceremony in Planaltina, on the outskirts of Brasília.
"My spiritual channels become more accessible, I can communicate better with myself," Souza said.
Gathered in a house courtyard and dressed in white, the group of mostly novices waited for more seasoned practitioners to enter a trance and bring messages from ancient spirits.
Meanwhile, back in the lab, Araujo is hoping to expand his DMT research to a study of 100 patents.
"Let's say that in five years we'll have... a clear picture on when it will reach a real clinical setting," he said.
X.Cheung--CPN